3 citations
,
September 2024 in “JAAD reviews.” Topical corticosteroids are recommended first for treating pediatric alopecia areata due to their safety and ease of use.
4 citations
,
January 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.
227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
10 citations
,
January 2023 in “Journal of the European Academy of Dermatology and Venereology” Alopecia areata greatly affects people's life quality, mental health, and work life.
January 2023 in “Przegla̧d dermatologiczny” There are two main types of alopecia areata with different severity, and diagnosis is made through clinical examination and trichoscopy, influencing treatment choices.
34 citations
,
November 2022 in “Clinical and Experimental Dermatology” People with alopecia areata are more likely to have other immune-related conditions.
25 citations
,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
11 citations
,
January 2022 in “Journal der Deutschen Dermatologischen Gesellschaft” Alopecia areata is a chronic condition causing hair loss, with new treatments targeting the immune system showing promise.
48 citations
,
April 2021 in “Journal of the American Academy of Dermatology” Topical corticosteroids are the best initial treatment for children's alopecia areata.
37 citations
,
December 2019 in “Giornale italiano di dermatologia e venereologia” The Italian guidelines offer advice for diagnosing and treating alopecia areata based on expert opinion and limited clinical trial evidence.
39 citations
,
January 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.
40 citations
,
September 2018 in “Journal of the American Academy of Dermatology” Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.
17 citations
,
March 2018 in “Pediatric dermatology” Hydroxychloroquine may help treat alopecia areata in children.
89 citations
,
March 2018 in “The Journal of Dermatology” Trichoscopy helps diagnose and monitor alopecia areata by looking at a combination of specific hair and scalp features.
49 citations
,
March 2017 in “Journal of the American Academy of Dermatology” Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
7 citations
,
January 2017 in “Dermatology” People who get alopecia areata after age 50 usually have mild symptoms, high chances of hair regrowth, and often have other health conditions.
139 citations
,
November 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
56 citations
,
October 2016 in “Journal of dermatological science” New insights into the causes and treatments for the autoimmune hair loss condition Alopecia areata have been made.
85 citations
,
October 2012 in “Dermatologic Clinics” Alopecia Areata is an autoimmune condition often starting before age 20, with varied treatment success and a need for personalized treatment plans.
218 citations
,
April 2012 in “British Journal of Dermatology” Guidelines suggest various treatments for alopecia areata, but leaving it untreated is also an option as 80% cases may recover on their own.
64 citations
,
November 2008 in “Journal of The American Academy of Dermatology” A new type of rapid hair loss called ADTA usually gets better on its own within 6 months.
